Los Angeles, CA – November 7, 2025 -The Terasaki Institute proudly announces that Johnson V. John, Ph.D., Assistant Professor at the Institute, has been appointed as a standing member of the Musculoskeletal Tissue Engineering (MTE) Study Section within the Center for Scientific Review at the National Institutes of Health (NIH). His four-year term is scheduled to begin in November 2025.
Los Angeles, CA – October 21, 2025 - The Terasaki Institute had the honor of hosting the Royal Belgian Economic Mission this past week, marking a significant step forward in fostering international collaboration between Belgium and California’s biomedical communities. The delegation’s visit to the Institute’s Woodland Hills facility was part of a larger program organized by the Belgian Foreign Trade Agency (BFTA) and Flanders Investment & Trade (FIT).
Los Angeles, CA – October 2, 2025 - The Terasaki Institute for Biomedical Innovation (TIBI) announces a leadership transition as Dr. Ali Khademhosseini concluded his tenure as Chief Executive Officer and Executive Director. He is pursuing entrepreneurial ventures at the intersection of artificial intelligence and biomedical innovation. We wish Dr. Khademhosseini well in his future endeavors.
Los Angeles, CA – September 23, 2025 - A research team at the Terasaki Institute, led by Dr. Vadim Jucaud in collaboration with Dr. Jing Yong Ye from the University of Texas San Antonio, has developed a new microfluidic-based biosensing platform that allows monitoring cellular secretion of monoclonal antibody in real time. This approach can make monoclonal antibody production more efficient, ultimately lowering manufacturing costs so these important biotherapeutics become more accessible to patients.
Los Angeles, CA – September 5, 2025 - Researchers have harnessed the power of artificial intelligence to tackle one of the most complex challenges in immunology: predicting how T cells recognize and respond to specific peptide antigens. Using AlphaFold 3 (AF3), a AI/ML model, designed for protein structure prediction, the team demonstrated a novel approach to model T cell receptor–peptide/major histocompatibility complex (TCR-pMHC) interactions with growing accuracy.
Los Angeles, CA –September 3, 2025 – Dr. Vadim Jucaud's lab at the Terasaki Institute has developed a human vascularized liver cancer-on-a-chip model to evaluate vessel remodeling and cell death in response to embolic agents.
Los Angeles, CA – August 14, 2025 – The Terasaki Institute for Biomedical Innovation is pleased to announce its 2025 Media Contest, inviting creative individuals worldwide to visually explore the fields of biomedical science and engineering. The contest accepts submissions in video, animation, and image formats—including AI-generated art—that capture the innovative spirit driving advances in healthcare.
Los Angeles, CA – August 14, 2025 - The Terasaki Institute for Biomedical Innovation announces a significant advancement in addressing the fight against cancer-associated cachexia (CAC), a life-threatening syndrome responsible for over one-third of cancer-related deaths. Published in Cell, the study led by Dr. Aliesha O’Raw, Principal Investigator at the Institute, demonstrates that modulating the vagus nerve can effectively halt the progression of cachexia, enhance chemotherapy outcomes, and improve survival in preclinical models.